DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneMPSvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Full Letter From Takeda to the National MPS Society
On behalf of Takeda, we are writing to share some disappointing news with the Hunter syndrome community regarding Takeda’s investigational intrathecal enzyme replacement therapy (ERT), TAK-609, for the potential treatment of pediatric patients with Hunter syndrome (mucopolysaccharidosis II / MPS II) and cognitive impairment.
After an eight-year journey, Takeda has made the difficult decision to discontinue development of TAK609 and will not proceed with regulatory submissions to the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other health authorities. We recognize this is not the decision we all hoped for when Shire (acquired by Takeda in 2019) set out to find a treatment that could address the debilitating cognitive effects of this disease. Several members of our Takeda team have been working on this program, alongside the MPS II patient community, since the beginning, so we understand the sadness we all share about this outcome.
Related Content
-
education[Pharmacological Property, Mechanism of Action and Clinical Study Results of Pabinafusp Alfa (Genetical Recombinatio...Mucopolysaccharidosis type II (MPS II) i...
-
educationiPS-Derived Neural Stem Cells for Disease Modeling and Evaluation of Therapeutics for Mucopolysaccharidosis Type IIMucopolysaccharidosis type II (MPS II), ...
-
educationA 1-Year and 4-Month-Old Child With Mucopolysaccharidoses Type II: A Clinical Case Report From EthiopiaMucopolysaccharidoses (MPSs) are a class...
-
educationMucopolysaccharidosis Type II: A Kenyan Case SeriesHunter syndrome, or mucopolysaccharidosi...
-
educationExpanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
educationGolgi Requires a New Casting in the Screenplay of Mucopolysaccharidosis II CytopathologyLysosome (L), a hydrolytic compartment o...
-
educationImpact of the COVID-19 Pandemic on the Standard of Care for Patients With Lysosomal Storage Diseases: A Survey of He...The impact of the COVID-19 pandemic on t...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email
Want to find the info you need faster?
The symptoms of Mucopolysaccharidosis and the treatments that are available vary depending on which type of Mucopolysaccharidosis a patient has been diagnosed with. Select which type you want to learn more about, and can highlight the resources that are most relevant to your MPS/ML type.
Not now